Krystal Biotech Inc (KRYS) Stock Price, Quote & News

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treati...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 586 5830

Website: www.krystalbio.com

Address:

2100 Wharton Street, Suite 701, Pittsburgh, United States

enriquesaaa Sep. 10 at 3:27 PM

$KRYS does anyone know the reason behind the fall these past days?

1 · Reply

kenny91655 Sep. 9 at 5:30 PM

$KRYS PDUFA for caregiver or self administration in US this week I believe.

0 · Reply

NVDAMillionaire Sep. 8 at 3:46 PM

$KRYS Really good write-up that perfectly summarizes KRYS's present situation. So if you want to bring your KRYS knowledge up to date or just discover KRYS, this is required reading. https://beyondspx.com/quote/KRYS/analysis/krystal-biotech-vyjuvek-s-global-ascent-and-a-multi-organ-gene-therapy-platform-unlocked-nasdaq-krys

0 · Reply

ZManicItalian Sep. 5 at 1:51 PM

$KRYS time to push toward $160+. US sales to keep expanding ,International sales soon to come online, plus multiple data readouts within next quarter or 2. I'm really looking forward to readout on cystic fibrosis. Solid cf data could allow them to take up majority market share there as it should work no matter which mutation a patient has. Also, KRYS is just starting to look at partnering or spinning of the Jeune assets (from Cantor conference talk yesterday). 🍻🐂

0 · Reply

JarvisFlow Aug. 22 at 12:30 PM

Chardan Capital updates rating for Krystal Biotech ( $KRYS ) to Buy, target set at 219 → 216.

0 · Reply

kenny91655 Aug. 21 at 4:34 PM

$KRYS Didn't hear Krish touch on this yet In the first quarter of 2025, the Company and certain of its employees received subpoenas from the U.S. Department of Justice requesting that the Company produce certain documents regarding its sponsored genetic testing program relating to VYJUVEK and commercial practices relating thereto. The Company is cooperating and providing information in response to the subpoenas. It is not possible to estimate the amount of any loss or range of possible loss that might result from this inquiry, and because the final outcome cannot be predicted with certainty, unfavorable or unexpected developments or outcomes could result in a material impact to the Company’s results of operations.

0 · Reply

Thestocktraderhubzee Aug. 21 at 4:15 PM

$KRYS Krystal Biotech Granted An End Of Phase 2 Meeting With The FDA In October To Discuss Registration Path For Inhaled KB707 Following NSCLC Data

0 · Reply

ZManicItalian Aug. 14 at 8:17 PM

$KRYS $160+ incoming 🍻🐂

0 · Reply

ZManicItalian Aug. 13 at 2:08 PM

$KRYS like these green days 🤑

0 · Reply

ZManicItalian Aug. 12 at 11:17 PM

$KRYS let's get back above $160! Foreign markets on deck 🤑👍 🍻🐂

0 · Reply

Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update

Aug 21, 2025, 12:11 PM EDT - 21 days ago

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

Aug 4, 2025, 12:42 PM EDT - 5 weeks ago

Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

Jul 25, 2025, 9:00 AM EDT - 6 weeks ago

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Jul 24, 2025, 8:00 AM EDT - 7 weeks ago

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Jul 9, 2025, 7:00 AM EDT - 2 months ago

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Jun 24, 2025, 7:00 AM EDT - 2 months ago

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

May 7, 2025, 8:00 AM EDT - 4 months ago

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

May 6, 2025, 2:43 PM EDT - 4 months ago

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 7:00 AM EDT - 4 months ago

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Apr 24, 2025, 8:00 AM EDT - 5 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 7, 2025, 4:30 PM EDT - 5 months ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Mar 24, 2025, 8:30 AM EDT - 6 months ago

Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK

Feb 28, 2025, 7:40 AM EST - 6 months ago

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Feb 21, 2025, 8:15 AM EST - 7 months ago

Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus

Feb 19, 2025, 11:43 AM EST - 7 months ago

Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 7:00 AM EST - 7 months ago

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 10:20 AM EST - 7 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE MARA MP

Jan 14, 2025, 8:00 AM EST - 8 months ago

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Dec 27, 2024, 8:30 AM EST - 9 months ago

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

Dec 18, 2024, 8:00 AM EST - 9 months ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Dec 9, 2024, 4:15 PM EST - 9 months ago

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Nov 27, 2024, 7:00 AM EST - 10 months ago

Krystal Biotech to Present at Upcoming Investor Conferences

Nov 6, 2024, 7:00 AM EST - 11 months ago

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 4, 2024, 3:31 PM EST - 11 months ago

Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 7:00 AM EDT - 11 months ago

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Oct 14, 2024, 4:58 PM EDT - 11 months ago

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:10 PM EDT - 1 year ago

Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 11:13 PM EDT - 1 year ago

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

Jul 26, 2024, 8:00 AM EDT - 1 year ago

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

May 15, 2024, 8:08 AM EDT - 1 year ago

Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB

May 15, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

May 6, 2024, 11:44 AM EDT - 1 year ago

Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript

May 6, 2024, 8:00 AM EDT - 1 year ago

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

May 2, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Apr 26, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Apr 4, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Mar 14, 2024, 5:34 PM EDT - 1 year ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRRO MREO TAK WVE

Feb 28, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 11:47 AM EST - 1 year ago

Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 8:00 AM EST - 1 year ago

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Feb 13, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

Feb 8, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Feb 1, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 4, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

enriquesaaa Sep. 10 at 3:27 PM

$KRYS does anyone know the reason behind the fall these past days?

1 · Reply

kenny91655 Sep. 9 at 5:30 PM

$KRYS PDUFA for caregiver or self administration in US this week I believe.

0 · Reply

NVDAMillionaire Sep. 8 at 3:46 PM

0 · Reply

ZManicItalian Sep. 5 at 1:51 PM

0 · Reply

JarvisFlow Aug. 22 at 12:30 PM

Chardan Capital updates rating for Krystal Biotech ( $KRYS ) to Buy, target set at 219 → 216.

0 · Reply

kenny91655 Aug. 21 at 4:34 PM

0 · Reply

Thestocktraderhubzee Aug. 21 at 4:15 PM

$KRYS Krystal Biotech Granted An End Of Phase 2 Meeting With The FDA In October To Discuss Registration Path For Inhaled KB707 Following NSCLC Data

0 · Reply

ZManicItalian Aug. 14 at 8:17 PM

$KRYS $160+ incoming 🍻🐂

0 · Reply

ZManicItalian Aug. 13 at 2:08 PM

$KRYS like these green days 🤑

0 · Reply

ZManicItalian Aug. 12 at 11:17 PM

$KRYS let's get back above $160! Foreign markets on deck 🤑👍 🍻🐂

0 · Reply

LetsRide_ Aug. 12 at 5:41 PM

$KRYS 👀

0 · Reply

enriquesaaa Aug. 6 at 3:00 PM

$KRYS It’ll happen soon. Probably some institution wanted in at lower prices and they dumped it with the excuse of lower q3. Maybe it was BoFA or any of their customers because they were first to reduce target price. We’re now in accumulation phase.

0 · Reply

LetsRide_ Aug. 6 at 1:33 PM

$KRYS patiently waiting for a rebound..

0 · Reply

JarvisFlow Aug. 5 at 5:52 PM

Citigroup has adjusted their stance on Krystal Biotech ( $KRYS ), setting the rating to Neutral with a target price of 176 → 166.

0 · Reply

ZacksResearch Aug. 5 at 5:30 PM

$KRYS drops 14% despite Q2 beat — what's behind the slide? 📉 Krystal Biotech reported EPS of $1.29, topping the Zacks Consensus Estimate of $1.08, and revenues from sales of Vyjuvek surged 36.6% YoY. However, soft guidance for third-quarter revenues spooked investors, leading to the decline. Full breakdown here 👉 https://www.zacks.com/stock/news/2667254/krys-q2-earnings-and-sales-top-estimates-stock-down-on-q3-outlook?cid=sm-stocktwits-2-2667254-body-5966&ADID=SYND_STOCKTWITS_TWEET_2_2667254_BODY_5966

0 · Reply

ZacksResearch Aug. 5 at 1:27 PM

$KRYS beat Q2 on both earnings and sales — so why the 14% drop? 👀 Vyjuvek delivered strong numbers, but Q3 revenue guidance came in soft, spooking the Street. Full story here 👉 https://www.zacks.com/stock/news/2667254/krys-q2-earnings-and-sales-top-estimates-stock-down-on-q3-outlook?cid=sm-stocktwits-2-2667254-teaser-5934&ADID=SYND_STOCKTWITS_TWEET_2_2667254_TEASER_5934

0 · Reply

JarvisFlow Aug. 5 at 10:30 AM

Chardan Capital has adjusted their stance on Krystal Biotech ( $KRYS ), setting the rating to Buy with a target price of 219.

0 · Reply

EarningsCentral Aug. 5 at 3:15 AM

$KRYS Q2 FY25 Earnings Beat | VYJUVEK Margins, EU Launch, & KB707 Pipeline Update https://youtu.be/ZLvjYZ2Eb_U

0 · Reply

KangaroooJack Aug. 5 at 1:09 AM

$KRYS You guys can thank me later for this $PROP

1 · Reply

buymoremakemore Aug. 4 at 10:32 PM

$KRYS Wont be surprised to see rebound tomorrow

0 · Reply

TKkamen Aug. 4 at 8:18 PM

$KRYS I’m so confused. This is such an overreaction.

0 · Reply

LetsRide_ Aug. 4 at 4:06 PM

$KRYS Overreaction.

0 · Reply

Market Cap	3.98B
Revenue (ttm)	290.52M
Net Income (ttm)	89.16M
EPS (ttm)	N/A
PE Ratio	28.70
Forward PE	29.88
Profit Margin	30.69%
Debt to Equity Ratio	0.00

Volume	318,800
Avg Vol	336,606
Day's Range	N/A - N/A
Shares Out	28.94M
Stochastic %K	47%
Beta	0.66
Analysts	Strong Sell
Price Target	$207.30